Abiopharma

🔍 WRIGHT LISA (Executive)

Company: Vericel Corp (VCEL)

Report Date: 2026-04-29

Detailed Transactions and Holdings:

• Acquired 3,200 shares of Common Stock (Direct)
  Date: 2026-04-29 | Code: M | equity_swap_involved: 0 | shares_owned_after: 15,851.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 3,200 shares of Restricted Stock Unit (Derivative)
  Date: 2026-04-29 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3, F2, F4, F5
• Acquired 8,000 shares of Stock Option (Right to Buy) at $33.43 per share (Derivative)
  Date: 2026-04-29 | Code: A | Expires: 2036-04-29 | equity_swap_involved: 0 | shares_owned_after: 8,000.00 | transaction_form_type: 4 | Footnotes: F6
• Acquired 3,200 shares of Restricted Stock Unit (Derivative)
  Date: 2026-04-29 | Code: A | equity_swap_involved: 0 | shares_owned_after: 3,200.00 | transaction_form_type: 4 | Footnotes: F3, F7, F5

Footnotes:

• F1: The Restricted Stock Units (RSUs) converted to Phantom Stock units and are deferred under the Vericel Corporation Deferred Compensation Plan. The units will be payable only in shares of Common Stock upon the Reporting Person's elected Benefit Distribution Date.
• F2: Upon the vesting of RSUs granted to the Reporting Person on April 30, 2025, the Reporting Person deferred the receipt of 3,200 shares of Common Stock and instead received 3,200 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan.
• F3: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.
• F4: These RSUs vest 100% on the earlier of April 30, 2026, or the date of the first Annual Meeting of Stockholders following April 30, 2025.
• F5: No expiration date for this type of award.
• F6: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company.
• F7: These RSUs vest 100% on the earlier of April 29, 2027, or the date of the first Annual Meeting of Stockholders following April 29, 2026.